Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016179 · ClinicalTrials.gov registry record · Phase 1
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
A Phase 1 study of Malignant Pleural Effusion and Malignant Ascites, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06016179: Recruiting Phase 1 study of Malignant Pleural Effusion and Malignant Ascites, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
NCT06016179 is a Phase 1 study of Malignant Pleural Effusion and Malignant Ascites that is actively recruiting participants, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 12 participants, below the 51-participant average among 3 other Malignant Pleural Effusion trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06016179, a Phase 1 study of Malignant Pleural Effusion and Malignant Ascites, is actively recruiting participants, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Primary Outcome
Number of patients with successful administration of tocilizumab
Conditions Studied
Interventions
- DRUG Tocilizumab
Study Locations (1)
Pennsylvania
- Allegheny Health Network Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)34 total trials
What NCT06016179 shows while recruiting
NCT06016179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 51-participant average among 3 other Malignant Pleural Effusion trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Malignant Pleural Effusion appearing as the primary indexed condition, and to 1 intervention - of which Tocilizumab is the first listed.
NCT06016179 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06016179 about?
NCT06016179 is a clinical study titled "Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer". The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previo...
What is the current status of trial NCT06016179?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-01-30. Estimated completion is 2027-01.
What conditions does trial NCT06016179 study?
This clinical trial studies the following conditions: Malignant Pleural Effusion, Malignant Ascites.
What interventions are being tested in trial NCT06016179?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT06016179?
This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06016179 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pleural Effusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RECRUITING · Phase 1
-
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
UNC Pleural Fluid Registry
RECRUITING
-
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI